Concepts (242)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 37 | 2026 | 1018 | 3.590 |
Why?
|
| Schools, Medical | 5 | 2018 | 135 | 2.170 |
Why?
|
| Students, Medical | 10 | 2022 | 449 | 2.060 |
Why?
|
| China | 24 | 2026 | 277 | 2.010 |
Why?
|
| Anti-HIV Agents | 12 | 2026 | 211 | 1.790 |
Why?
|
| Education, Medical | 6 | 2019 | 229 | 1.500 |
Why?
|
| Education, Medical, Undergraduate | 3 | 2019 | 189 | 1.360 |
Why?
|
| Pre-Exposure Prophylaxis | 8 | 2026 | 206 | 1.330 |
Why?
|
| Curriculum | 8 | 2019 | 633 | 1.120 |
Why?
|
| Homosexuality, Male | 7 | 2026 | 342 | 0.970 |
Why?
|
| Attitude of Health Personnel | 4 | 2019 | 685 | 0.880 |
Why?
|
| Immunocompromised Host | 2 | 2023 | 139 | 0.810 |
Why?
|
| Women's Health | 2 | 2019 | 119 | 0.700 |
Why?
|
| Teaching | 3 | 2017 | 143 | 0.670 |
Why?
|
| Medication Adherence | 4 | 2026 | 130 | 0.670 |
Why?
|
| Internship and Residency | 4 | 2019 | 1123 | 0.660 |
Why?
|
| Anti-Retroviral Agents | 5 | 2023 | 36 | 0.650 |
Why?
|
| Educational Measurement | 4 | 2019 | 241 | 0.650 |
Why?
|
| Transplant Recipients | 1 | 2021 | 182 | 0.590 |
Why?
|
| International Cooperation | 2 | 2013 | 132 | 0.590 |
Why?
|
| HIV-1 | 5 | 2007 | 179 | 0.560 |
Why?
|
| Antiretroviral Therapy, Highly Active | 6 | 2003 | 73 | 0.550 |
Why?
|
| Cardiovascular Diseases | 3 | 2014 | 802 | 0.540 |
Why?
|
| Ethics, Medical | 2 | 2017 | 292 | 0.530 |
Why?
|
| Reference Standards | 1 | 2018 | 146 | 0.520 |
Why?
|
| Neurosciences | 2 | 2016 | 52 | 0.510 |
Why?
|
| Medicine, Chinese Traditional | 1 | 2017 | 9 | 0.510 |
Why?
|
| Geriatrics | 1 | 2018 | 67 | 0.510 |
Why?
|
| Neurologists | 1 | 2016 | 10 | 0.490 |
Why?
|
| Humans | 61 | 2026 | 98088 | 0.490 |
Why?
|
| Neurosurgeons | 1 | 2016 | 48 | 0.480 |
Why?
|
| Health Care Reform | 1 | 2017 | 78 | 0.470 |
Why?
|
| Acquired Immunodeficiency Syndrome | 4 | 2019 | 68 | 0.470 |
Why?
|
| Sexual and Gender Minorities | 3 | 2026 | 262 | 0.470 |
Why?
|
| Telemedicine | 3 | 2026 | 250 | 0.460 |
Why?
|
| Surveys and Questionnaires | 9 | 2024 | 3022 | 0.450 |
Why?
|
| Reverse Transcriptase Inhibitors | 3 | 2005 | 21 | 0.440 |
Why?
|
| Histology | 1 | 2014 | 4 | 0.440 |
Why?
|
| Career Choice | 1 | 2016 | 161 | 0.440 |
Why?
|
| Physiology | 1 | 2014 | 17 | 0.430 |
Why?
|
| Health Communication | 1 | 2014 | 15 | 0.420 |
Why?
|
| Internal Medicine | 1 | 2018 | 338 | 0.420 |
Why?
|
| Emtricitabine | 4 | 2026 | 14 | 0.410 |
Why?
|
| Tenofovir | 4 | 2026 | 18 | 0.410 |
Why?
|
| Mental Health Services | 2 | 2014 | 97 | 0.400 |
Why?
|
| Communication | 2 | 2014 | 455 | 0.390 |
Why?
|
| Cross Infection | 1 | 2015 | 155 | 0.390 |
Why?
|
| Health Services Accessibility | 3 | 2011 | 532 | 0.390 |
Why?
|
| Competency-Based Education | 3 | 2019 | 37 | 0.380 |
Why?
|
| Suicidal Ideation | 1 | 2014 | 88 | 0.380 |
Why?
|
| Drugs, Generic | 1 | 2013 | 21 | 0.370 |
Why?
|
| Male | 30 | 2026 | 47077 | 0.370 |
Why?
|
| Clostridium Infections | 1 | 2015 | 132 | 0.370 |
Why?
|
| Adult | 25 | 2026 | 29539 | 0.370 |
Why?
|
| Diffusion of Innovation | 1 | 2013 | 81 | 0.370 |
Why?
|
| Delivery of Health Care | 3 | 2011 | 480 | 0.350 |
Why?
|
| Cross-Sectional Studies | 7 | 2019 | 2037 | 0.350 |
Why?
|
| Depression | 2 | 2014 | 617 | 0.350 |
Why?
|
| Health Care Surveys | 3 | 2017 | 282 | 0.350 |
Why?
|
| HIV Protease Inhibitors | 4 | 2007 | 21 | 0.340 |
Why?
|
| Faculty, Medical | 3 | 2019 | 193 | 0.330 |
Why?
|
| Patient Education as Topic | 1 | 2014 | 417 | 0.320 |
Why?
|
| Physician-Patient Relations | 2 | 2014 | 580 | 0.310 |
Why?
|
| Young Adult | 11 | 2026 | 7507 | 0.310 |
Why?
|
| Female | 25 | 2024 | 51541 | 0.290 |
Why?
|
| Antiviral Agents | 3 | 2023 | 369 | 0.290 |
Why?
|
| Preventive Health Services | 1 | 2008 | 38 | 0.270 |
Why?
|
| Health Knowledge, Attitudes, Practice | 3 | 2018 | 601 | 0.260 |
Why?
|
| Clinical Competence | 4 | 2018 | 865 | 0.260 |
Why?
|
| Mentors | 2 | 2018 | 103 | 0.240 |
Why?
|
| Patient Compliance | 4 | 2003 | 245 | 0.230 |
Why?
|
| Qualitative Research | 3 | 2024 | 414 | 0.230 |
Why?
|
| Health Education | 2 | 2012 | 109 | 0.220 |
Why?
|
| Hospitalization | 2 | 2021 | 991 | 0.220 |
Why?
|
| Neoplasms | 1 | 2021 | 3340 | 0.220 |
Why?
|
| Middle Aged | 16 | 2026 | 29428 | 0.220 |
Why?
|
| Drug Therapy, Combination | 6 | 2007 | 764 | 0.210 |
Why?
|
| Sulfonamides | 1 | 2007 | 351 | 0.210 |
Why?
|
| Facial Neuralgia | 1 | 2024 | 2 | 0.210 |
Why?
|
| Peer Group | 1 | 2025 | 99 | 0.200 |
Why?
|
| Developing Countries | 1 | 2004 | 101 | 0.200 |
Why?
|
| Global Health | 1 | 2005 | 215 | 0.200 |
Why?
|
| Cell Phone | 1 | 2023 | 39 | 0.200 |
Why?
|
| Referral and Consultation | 2 | 2025 | 418 | 0.190 |
Why?
|
| Hyperlipidemias | 1 | 2003 | 92 | 0.190 |
Why?
|
| Indinavir | 1 | 2002 | 3 | 0.190 |
Why?
|
| Adolescent | 8 | 2021 | 10080 | 0.190 |
Why?
|
| Education, Medical, Graduate | 2 | 2018 | 449 | 0.190 |
Why?
|
| Program Evaluation | 3 | 2024 | 346 | 0.190 |
Why?
|
| Crowdsourcing | 1 | 2022 | 12 | 0.190 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2023 | 66 | 0.180 |
Why?
|
| Poverty | 1 | 2004 | 215 | 0.180 |
Why?
|
| Mobile Applications | 1 | 2023 | 83 | 0.180 |
Why?
|
| Continuity of Patient Care | 1 | 2024 | 179 | 0.180 |
Why?
|
| Patient Satisfaction | 1 | 2005 | 511 | 0.180 |
Why?
|
| Immunoglobulin G | 1 | 2023 | 480 | 0.160 |
Why?
|
| Social Support | 1 | 2002 | 246 | 0.160 |
Why?
|
| Cryptococcus neoformans | 1 | 2019 | 8 | 0.150 |
Why?
|
| Cryptococcosis | 1 | 2019 | 9 | 0.150 |
Why?
|
| Opportunistic Infections | 1 | 2019 | 57 | 0.150 |
Why?
|
| Viral Load | 5 | 2007 | 161 | 0.150 |
Why?
|
| Reproductive Health | 1 | 2019 | 36 | 0.150 |
Why?
|
| Licensure, Medical | 1 | 2019 | 20 | 0.150 |
Why?
|
| Substance Abuse, Intravenous | 1 | 2000 | 76 | 0.140 |
Why?
|
| HIV Wasting Syndrome | 1 | 1998 | 2 | 0.140 |
Why?
|
| Prevalence | 3 | 2015 | 1384 | 0.140 |
Why?
|
| Primary Health Care | 1 | 2002 | 395 | 0.140 |
Why?
|
| Retrospective Studies | 6 | 2022 | 10973 | 0.140 |
Why?
|
| Patient Discharge | 1 | 2021 | 381 | 0.130 |
Why?
|
| Gynecology | 1 | 2019 | 135 | 0.130 |
Why?
|
| Chicago | 5 | 2002 | 1513 | 0.130 |
Why?
|
| Hospice Care | 1 | 2017 | 41 | 0.130 |
Why?
|
| Respiration, Artificial | 1 | 2021 | 462 | 0.130 |
Why?
|
| Capacity Building | 1 | 2017 | 14 | 0.130 |
Why?
|
| Problem-Based Learning | 1 | 2017 | 44 | 0.130 |
Why?
|
| Universities | 1 | 2018 | 166 | 0.130 |
Why?
|
| Aged, 80 and over | 2 | 2021 | 7389 | 0.130 |
Why?
|
| Zidovudine | 1 | 1996 | 12 | 0.120 |
Why?
|
| Comprehensive Health Care | 1 | 1996 | 13 | 0.120 |
Why?
|
| Models, Organizational | 1 | 1996 | 47 | 0.120 |
Why?
|
| Cohort Studies | 4 | 2025 | 3212 | 0.120 |
Why?
|
| Fellowships and Scholarships | 1 | 2018 | 164 | 0.120 |
Why?
|
| Risk Factors | 4 | 2014 | 6233 | 0.110 |
Why?
|
| Data Collection | 2 | 2014 | 376 | 0.110 |
Why?
|
| Education, Public Health Professional | 1 | 2015 | 2 | 0.110 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 1996 | 70 | 0.110 |
Why?
|
| Palliative Care | 1 | 2017 | 290 | 0.110 |
Why?
|
| United States | 4 | 2019 | 8197 | 0.110 |
Why?
|
| Learning | 1 | 2018 | 310 | 0.110 |
Why?
|
| Quality of Health Care | 1 | 2018 | 391 | 0.110 |
Why?
|
| HIV Seroprevalence | 1 | 1994 | 9 | 0.100 |
Why?
|
| Self-Assessment | 1 | 2014 | 45 | 0.100 |
Why?
|
| Professional-Patient Relations | 1 | 2014 | 48 | 0.100 |
Why?
|
| Specialization | 1 | 2014 | 69 | 0.100 |
Why?
|
| Aged | 4 | 2021 | 21758 | 0.100 |
Why?
|
| Clinical Trials as Topic | 3 | 2024 | 1129 | 0.100 |
Why?
|
| Health Surveys | 1 | 2014 | 254 | 0.100 |
Why?
|
| Syphilis | 1 | 1994 | 38 | 0.100 |
Why?
|
| Neurology | 1 | 2014 | 84 | 0.100 |
Why?
|
| Focus Groups | 1 | 2014 | 214 | 0.090 |
Why?
|
| Feasibility Studies | 2 | 2026 | 801 | 0.090 |
Why?
|
| Patient Medication Knowledge | 1 | 2012 | 1 | 0.090 |
Why?
|
| Biomedical Research | 1 | 2017 | 471 | 0.090 |
Why?
|
| Sexually Transmitted Diseases | 1 | 1994 | 114 | 0.090 |
Why?
|
| Attitude | 1 | 2013 | 133 | 0.090 |
Why?
|
| Quality Improvement | 1 | 2016 | 520 | 0.090 |
Why?
|
| Directive Counseling | 1 | 2012 | 34 | 0.090 |
Why?
|
| Administration, Oral | 2 | 2026 | 674 | 0.090 |
Why?
|
| Psychiatry | 1 | 2013 | 92 | 0.090 |
Why?
|
| Truth Disclosure | 1 | 2012 | 75 | 0.090 |
Why?
|
| Physician's Role | 2 | 1996 | 181 | 0.080 |
Why?
|
| Social Stigma | 1 | 2012 | 95 | 0.080 |
Why?
|
| HIV Seropositivity | 2 | 1988 | 50 | 0.080 |
Why?
|
| Drug Monitoring | 1 | 2012 | 166 | 0.080 |
Why?
|
| Body Mass Index | 1 | 2014 | 850 | 0.080 |
Why?
|
| Smoking | 1 | 2014 | 674 | 0.080 |
Why?
|
| Pilot Projects | 2 | 2023 | 977 | 0.080 |
Why?
|
| Child | 4 | 2004 | 7681 | 0.080 |
Why?
|
| Drug Resistance, Viral | 2 | 2007 | 37 | 0.080 |
Why?
|
| Interviews as Topic | 2 | 2024 | 387 | 0.080 |
Why?
|
| Urban Population | 2 | 2002 | 246 | 0.070 |
Why?
|
| Longitudinal Studies | 1 | 2013 | 1284 | 0.070 |
Why?
|
| Hypertension | 1 | 2014 | 778 | 0.070 |
Why?
|
| Role | 1 | 1988 | 9 | 0.070 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2022 | 1012 | 0.070 |
Why?
|
| Darunavir | 1 | 2007 | 1 | 0.060 |
Why?
|
| Treatment Outcome | 3 | 2019 | 9711 | 0.060 |
Why?
|
| Program Development | 2 | 2018 | 141 | 0.060 |
Why?
|
| CD4 Lymphocyte Count | 2 | 2004 | 75 | 0.060 |
Why?
|
| Nurse Practitioners | 2 | 2017 | 36 | 0.060 |
Why?
|
| Physician Assistants | 2 | 2017 | 32 | 0.060 |
Why?
|
| Text Messaging | 1 | 2026 | 36 | 0.060 |
Why?
|
| Telephone | 1 | 2005 | 43 | 0.060 |
Why?
|
| Foster Home Care | 1 | 2004 | 9 | 0.050 |
Why?
|
| Nelfinavir | 1 | 2004 | 6 | 0.050 |
Why?
|
| Ritonavir | 1 | 2004 | 13 | 0.050 |
Why?
|
| Pyrimidinones | 1 | 2004 | 51 | 0.050 |
Why?
|
| Practice Guidelines as Topic | 2 | 2002 | 1110 | 0.050 |
Why?
|
| Case Management | 1 | 2002 | 29 | 0.050 |
Why?
|
| Transportation of Patients | 1 | 2002 | 36 | 0.050 |
Why?
|
| Republic of Korea | 2 | 2012 | 41 | 0.040 |
Why?
|
| Hospitals, Public | 1 | 2002 | 15 | 0.040 |
Why?
|
| Brazil | 2 | 2012 | 93 | 0.040 |
Why?
|
| Adenosine Monophosphate | 1 | 2021 | 31 | 0.040 |
Why?
|
| Australia | 2 | 2012 | 125 | 0.040 |
Why?
|
| Anticholesteremic Agents | 1 | 2003 | 164 | 0.040 |
Why?
|
| Alanine | 1 | 2021 | 82 | 0.040 |
Why?
|
| Health Personnel | 1 | 2024 | 257 | 0.040 |
Why?
|
| Europe | 2 | 2012 | 356 | 0.040 |
Why?
|
| Predictive Value of Tests | 2 | 2004 | 1782 | 0.040 |
Why?
|
| Mental Health | 1 | 2002 | 219 | 0.040 |
Why?
|
| Antigens, Fungal | 1 | 2019 | 6 | 0.040 |
Why?
|
| Fluconazole | 1 | 2019 | 11 | 0.040 |
Why?
|
| Amphotericin B | 1 | 2019 | 33 | 0.040 |
Why?
|
| Meningitis | 1 | 2019 | 22 | 0.040 |
Why?
|
| Patient Care Team | 1 | 2002 | 320 | 0.040 |
Why?
|
| Social Class | 1 | 2000 | 156 | 0.040 |
Why?
|
| Antifungal Agents | 1 | 2019 | 126 | 0.040 |
Why?
|
| Physicians | 2 | 2017 | 685 | 0.040 |
Why?
|
| Group Processes | 1 | 2017 | 30 | 0.030 |
Why?
|
| Formative Feedback | 1 | 2017 | 17 | 0.030 |
Why?
|
| Cultural Competency | 1 | 2017 | 23 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2026 | 4823 | 0.030 |
Why?
|
| Interprofessional Relations | 1 | 2017 | 122 | 0.030 |
Why?
|
| Guidelines as Topic | 1 | 2017 | 169 | 0.030 |
Why?
|
| Pandemics | 1 | 2022 | 916 | 0.030 |
Why?
|
| Survival Rate | 1 | 2000 | 2041 | 0.030 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 1994 | 24 | 0.030 |
Why?
|
| Seroepidemiologic Studies | 1 | 1994 | 58 | 0.030 |
Why?
|
| Time Factors | 1 | 2002 | 5567 | 0.020 |
Why?
|
| Cote d'Ivoire | 1 | 2012 | 2 | 0.020 |
Why?
|
| South Africa | 1 | 2012 | 63 | 0.020 |
Why?
|
| Educational Status | 1 | 2013 | 205 | 0.020 |
Why?
|
| Africa | 1 | 2012 | 111 | 0.020 |
Why?
|
| Prejudice | 1 | 2012 | 51 | 0.020 |
Why?
|
| Social Isolation | 1 | 2012 | 73 | 0.020 |
Why?
|
| Pregnancy | 2 | 1996 | 3244 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 1996 | 2529 | 0.020 |
Why?
|
| Sex Factors | 1 | 2013 | 1138 | 0.020 |
Why?
|
| Infant | 1 | 1996 | 3328 | 0.020 |
Why?
|
| Child, Preschool | 1 | 1996 | 4001 | 0.020 |
Why?
|
| Mass Screening | 1 | 1994 | 745 | 0.020 |
Why?
|
| Coccidiosis | 1 | 1987 | 2 | 0.020 |
Why?
|
| Cryptosporidiosis | 1 | 1987 | 7 | 0.020 |
Why?
|
| Confidentiality | 1 | 1988 | 77 | 0.020 |
Why?
|
| Diarrhea | 1 | 1987 | 180 | 0.020 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 1987 | 98 | 0.020 |
Why?
|
| Counseling | 1 | 1988 | 191 | 0.010 |
Why?
|
| Informed Consent | 1 | 1988 | 284 | 0.010 |
Why?
|
| Stavudine | 1 | 2004 | 4 | 0.010 |
Why?
|
| Lamivudine | 1 | 2004 | 13 | 0.010 |
Why?
|
| Lopinavir | 1 | 2004 | 6 | 0.010 |
Why?
|
| RNA, Viral | 1 | 2004 | 288 | 0.010 |
Why?
|
| Metabolic Diseases | 1 | 2003 | 60 | 0.010 |
Why?
|
| Sex Characteristics | 1 | 2004 | 351 | 0.010 |
Why?
|
| Nervous System Diseases | 1 | 2003 | 169 | 0.010 |
Why?
|
| Acute Disease | 1 | 2003 | 860 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2002 | 839 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 2004 | 1782 | 0.010 |
Why?
|
| Risk Assessment | 1 | 1988 | 2585 | 0.010 |
Why?
|
| Chronic Disease | 1 | 2003 | 985 | 0.010 |
Why?
|
| Feces | 1 | 1987 | 387 | 0.000 |
Why?
|